FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 22, 2025-

Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to treat adult patients with R/R FL after two or more lines of systemic therapy.

FDA Green Lights 'One-Minute' Injection for R/R Follicular Lymphoma Treatment

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or more prior treatments.

FDA Approves Subcutaneous Mosunetuzumab in Follicular Lymphoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA approves mosunetuzumab-axgb for quick subcutaneous treatment of relapsed follicular lymphoma, enhancing patient care and reducing clinic time.

Sub-Q Mosunetuzumab Wins FDA Approval in R/R Follicular Lymphoma

Subcutaneous mosunetuzumab wins FDA accelerated approval in patients with R/R follicular lymphoma following 2 or more lines of systemic therapy.

FDA Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

Data from the phase 1/2 GO29781 study support the approval of subcutaneous mosunetuzumab in this follicular lymphoma population.